-transparent.png){kind=logo}
In order to label D2 dopamine receptors selectively and covalently by means of a photosensitive compound, azidoclebopride was synthesized directly from clebopride. The dissociation constant (KD) of clebopride for the D2 dopamine receptor (canine brain striatum) was 1.5 nM, while that for azidoclebopride was 21 nM. The affinities of both clebopride and azidoclebopride were markedly reduced in the absence of sodium chloride. In the presence of ultraviolet light, azidoclebopride inactivated D2 dopamine receptors irreversibly, as indicated by the inability of the receptors to bind [3H]spiperone. Maximal photoinactivation of about 60% of the D2 dopamine receptors occurred at 1 microM azidoclebopride; 30% of the receptors were inactivated at 80 nM azidoclebopride (pseudo-IC50). Dopamine agonists selectively protected the D2 receptors from being inactivated by azidoclebopride, the order of potency being (-)-N-n-propylnorapomorphine greater than apomorphine greater than (+/-)-6,7-dihydroxy-2-aminotetralin greater than (+)-N-n-propylnorapomorphine greater than dopamine greater than noradrenaline greater than serotonin. Similarly, dopaminergic antagonists prevented the photoinactivation of D2 receptors by azidoclebopride with the following order of potency: spiperone greater than (+)-butaclamol greater than haloperidol greater than clebopride greater than (-)-sulpiride greater than (-)-butaclamol. The degree of D2 dopamine receptor photoinduced inactivation by azidoclebopride was not significantly affected by scavengers such as p-aminobenzoic acid and dithiothreitol. Furthermore, irradiation of striatal membranes with a concentration of azidoclebopride sufficient to inactivate dopamine D2 receptors by 60% did not significantly reduce dopamine D1, serotonin (S2), benzodiazepine, alpha 1- or beta-noradrenergic receptors. This study describes the use of a novel and selective photoaffinity ligand for brain dopamine D2 receptors. The molecule, in radiolabeled form, may aid in the molecular characterization of these receptors.
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
November 1984,
Life sciences,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
July 1985,
European journal of pharmacology,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
December 1986,
FEBS letters,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
January 1988,
Progress in neuro-psychopharmacology & biological psychiatry,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
November 1987,
FEBS letters,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
October 1995,
Biochemistry,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
January 2005,
Journal of molecular neuroscience : MN,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
July 1989,
Molecular pharmacology,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
September 1988,
Biochemical and biophysical research communications,
H B Niznik, and
J H Guan, and
J L Neumeyer, and
P Seeman
February 1993,
The Biochemical journal,
